









Markets
/
Stocks
/
nasdaq-vtgn
/

Vistagen Therapeutics Inc

VTGN

4.020USD

-0.160-3.83%

Close 11/06, 16:00（ET）Quotes delayed by 15 min

117.71MMarket Cap

LossP/E TTM



Vistagen Therapeutics Inc

4.020

-0.160-3.83%

Overview Company Financials Analysis

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

Overview

Company

Financials

Analysis

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score of Vistagen Therapeutics Inc

Currency: USD Updated: 2025-11-05

Key Insights

The company's fundamentals are relatively very healthy. Its valuation is considered fairly valued,and institutional recognition is very high. Over the past 30 days, multiple analysts have rated the company as a Strong Buy. Despite an average stock market performance, the company shows strong fundamentals and technicals. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Vistagen Therapeutics Inc's Score

Industry at a Glance

Industry Ranking

66 / 407

Overall Ranking

181 / 4616

Industry

Biotechnology & Medical Research

Support & Resistance

No Data

Score Analysis

Current score

Previous score

Analyst Rating

Based on 5 analysts

Strong Buy

Current Rating

14.500

Target Price

+256.27%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Vistagen Therapeutics Inc Highlights

StrengthsRisks

Vistagen Therapeutics, Inc. is a neuroscience-focused biopharmaceutical company. The Company is engaged in the development and commercialization of therapies for psychiatric and neurological disorders based on its understanding of nose-to-brain neurocircuitry. Its clinical-stage pipeline consists of intranasal product candidates from a new class of potential neuroscience therapies called pherines. Its diversified pipeline of pherine product candidates rapidly activate chemosensory neurons in the nasal cavity to impact fundamental neurocircuitry in the olfactory system and the brain. Its pipeline also includes an oral prodrug with potential to modulate N-methyl-D-aspartate receptor (NMDA) receptor activity. Its neuroscience pipeline includes five clinical-stage investigational agent, namely Fasedienol (PH94B), Itruvone (PH10), AV-101, PH15, PH80, and PH284.

Growing

The company is in a growing phase, with the latest annual income totaling USD 486.00K.

Undervalued

The company’s latest PE is -2.34, at a low 3-year percentile range.

Institutional Selling

The latest institutional holdings are 19.07M shares, decreasing 6.41% quarter-over-quarter.

Held by James Simons

Star Investor James Simons holds 40.50K shares of this stock.

Higher Market Activity

The company has more investor interest, with a 20-day turnover ratio of 0.41.

Financial Health

Currency: USD Updated: 2025-11-05

The company's current financial score is 7.79, which is higher than the Biotechnology & Medical Research industry's average of 6.92. Its financial status is robust, and its operating efficiency is low. Its latest quarterly revenue reached 244.00K, representing a year-over-year increase of 190.48%, while its net profit experienced a year-over-year increase of 40.64%.

Score

Industry at a Glance

Previous score

7.79

Change



Financials

10.00

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

No Data



Quality of Earnings

8.54

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

No Data



Operational Efficiency

2.86

Key Metrics

Cash flow from operating activities

Income after tax

No Data



Growth Potential

10.00

Key Metrics

Cash flow from operating activities

Total revenue

No Data



Shareholder Returns

7.58

Key Metrics

Free cash flow

No Data

Vistagen Therapeutics Inc's Company Valuation

Currency: USD Updated: 2025-11-05

The company’s current valuation score is 6.93, which is lower than the Biotechnology & Medical Research industry's average of 7.05. Its current P/E ratio is -2.34, which is -99.72% below the recent high of -0.01 and -85.24% above the recent low of -4.33.

Score

Industry at a Glance

Previous score

6.93

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 66/407

No Data

Earnings Forecast

Currency: USD Updated: 2025-11-05

The company’s current earnings forecast score is 9.20, which is higher than the Biotechnology & Medical Research industry's average of 8.00. The average price target for Vistagen Therapeutics Inc is 13.50, with a high of 19.00 and a low of 12.00.

Score

Industry at a Glance

Previous score

9.20

Change

Support & Resistance

No Data

Analyst Rating

Based on 5 analysts

Strong Buy

Current Rating

14.500

Target Price

+246.89%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

521

Total

Median

Average

Company name

Ratings

Analysts

Vistagen Therapeutics Inc

VTGN

CRISPR Therapeutics AG

CRSP

Ionis Pharmaceuticals Inc

IONS

argenx SE

ARGX

Intellia Therapeutics Inc

NTLA

IQVIA Holdings Inc

IQV

...

104

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

No Data

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2025-11-05

The company’s current price momentum score is 6.94, which is higher than the Biotechnology & Medical Research industry's average of 6.49. Sideways: Currently, the stock price is trading between the resistance level at 4.66 and the support level at 3.70, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

6.70

Change

0.24

Support & Resistance

No Data

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(3)

Neutral(4)

Buy(0)

Indicators

Value

Direction

MACD(12,26,9)

-0.051

Neutral

RSI(14)

52.170

Neutral

STOCH(KDJ)(9,3,3)

39.966

Neutral

ATR(14)

0.325

Low Volatility

CCI(14)

-14.025

Neutral

Williams %R

65.621

Sell

TRIX(12,20)

0.366

Sell

StochRSI(14)

3.862

Sell

Moving Average

Sell(2)

Neutral(0)

Buy(4)

Indicators

Value

Direction

MA5

4.090

Sell

MA10

4.018

Buy

MA20

4.060

Sell

MA50

3.718

Buy

MA100

3.178

Buy

MA200

2.852

Buy

Institutional Confidence

Currency: USD Updated: 2025-11-05

The company’s current institutional recognition score is 5.00, which is lower than the Biotechnology & Medical Research industry's average of 5.16. The latest institutional shareholding proportion is 63.87%, representing a quarter-over-quarter increase of 22.62%. The largest institutional shareholder is The Vanguard, holding a total of 1.69M shares, representing 5.65% of shares outstanding, with 20.78% decrease in holdings.

Score

Industry at a Glance

Previous score

5.00

Change

Institutional Shareholding

No Data

Shareholder Activity

Name

Shares Held

Chg %

Janus Henderson Investors

4.17M

TCG Crossover Management, LLC

2.68M

Nantahala Capital Management, LLC

1.98M

StemPoint Capital LP

1.80M

+2.67%

The Vanguard Group, Inc.

Star Investors

1.76M

-10.23%

Commodore Capital LP

1.57M

J.P. Morgan Securities LLC

748.85K

-0.27%

Ikarian Capital LLC

601.70K

Sphera Funds Management Ltd.

447.94K

-43.34%

Adar1 Capital Management LLC

420.76K

Risk Assessment

Currency: USD Updated: 2025-11-05

The company’s current risk assessment score is 2.95, which is lower than the Biotechnology & Medical Research industry's average of 3.47. The company's beta value is 0.57. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets.